Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA approves first treatment for chronic rhinosinusitis with nasal polyps


SILVER SPRING, Md., June 26, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

"Nasal polyps can lead to loss of smell and often patients require surgery to remove the polyps," said Sally Seymour, M.D., Director of the Division of Pulmonary, Allergy and Rheumatology Products in the FDA's Center for Drug Evaluation and Research. "Dupixent provides an important treatment option for patients whose nasal polyps are not adequately controlled with intranasal steroids. It also reduces the need for nasal polyp surgery and oral steroids." 

Dupixent is given by injection. The efficacy and safety of Dupixent were established in two studies with 724 patients, 18 years and older with chronic rhinosinusitis with nasal polyps who were symptomatic despite taking intranasal corticosteroids. Patients who received Dupixent had statistically significant reductions in their nasal polyp size and nasal congestion compared to the placebo group. Patients taking Dupixent also reported an increased ability to smell and required less nasal polyp surgery and oral steroids.

Dupixent may cause serious allergic reactions and eye problems, such as inflammation of the eye (conjunctivitis) and inflammation of the cornea (keratitis). If patients experience new or worsening eye symptoms, such as redness, itching, pain or visual changes, they should consult their health care professional. The most common side effects reported include injection site reactions as well as eye and eyelid inflammation, which included redness, swelling and itching. Patients receiving Dupixent should avoid receiving live vaccines.

Dupixent was originally approved in 2017 for patients 12 and older with eczema that is not controlled adequately by topical therapies or when those therapies are not advisable. In 2018, Dupixent was approved as an add-on maintenance treatment for patients 12 years and older with moderate-to-severe eosinophilic asthma or with oral corticosteroid-dependent asthma.

The FDA granted this application Priority Review. The approval of Dupixent was granted to Regeneron Pharmaceuticals.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Nathan Arnold, 301-796-6248, nathan.arnold@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration


These press releases may also interest you

at 21:30
Phreesia, Inc. ("Phreesia") , a leading patient intake management platform, announced today the pricing of the previously announced underwritten secondary offering of a total of 6,750,000 shares of its common stock at a price to the public of $26.00...

at 21:00
Fluor Corporation and Bayer placed the final steel beam today for Bayer's new cell culture technology center being constructed in Berkeley, California. The state-of-the-art, Single Use Technology (SUT), biopharmaceutical manufacturing facility will...

at 21:00
ZRT Laboratory is pleased to announce the launch of a new LCMS Saliva Steroid Profile to be added to the existing suite of saliva test offerings. While ZRT's salivary hormone immunoassays continue to provide highly accurate results, there are some...

at 20:30
The Bank's sustainable profit excluding one-offs came in at RUB 17.4 bn, growing by 23% as part of the net profit. Net interest income increased by 19% to RUB 40.6 bn, while net fee and commission income rose by 23% to RUB 18 bn. Retail Year to...

at 19:45
World Brand Lab today released its "2019 World's 500 Most Influential Brands" list. Benefiting from business growth in cloud computing and self-driving technology, last year's runner-up Google beat Amazon to top the list while Amazon dropped to...

at 19:24
Chronolife, an artificial intelligence company specializing in digital health, today announced the commercial launch of Nexkintm, a groundbreaking washable smart T-shirt that monitors six key physiological parameters to enable prevention, risk...



News published on 26 june 2019 at 16:36 and distributed by: